Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis
IntroductionThe use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.996553/full |
| _version_ | 1828097477465604096 |
|---|---|
| author | Maria Papathanassiou Ioannis Tamposis Kalliopi K. Exarchou-Kouveli Panagiota I. Kontou Anna Tzortzi de Paz Lampros Mitrakas Maria Samara Pantelis G. Bagos Vassilios Tzortzis Panagiotis J. Vlachostergios |
| author_facet | Maria Papathanassiou Ioannis Tamposis Kalliopi K. Exarchou-Kouveli Panagiota I. Kontou Anna Tzortzi de Paz Lampros Mitrakas Maria Samara Pantelis G. Bagos Vassilios Tzortzis Panagiotis J. Vlachostergios |
| author_sort | Maria Papathanassiou |
| collection | DOAJ |
| description | IntroductionThe use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA monoclonal antibodies.MethodsElectronic databases, including PubMed, EMBASE, Medline, Web of Science, and Cochrane Library, were comprehensively searched from inception to July 2022. Objective response rates (ORR), progression-free survival (PFS), and ≥ grade 3 adverse events (AEs) were assessed in the meta-analysis, along with corresponding 95% confidence intervals (CIs) and publication bias.ResultsTen studies which contained a total of 500 patients were included. The pooled ORR was 19% (95% CI: 10, 31), and PFS was 5.6 months (95% CI: 4.1, 7.8). There were ≥ grade 3 AEs noted in 25% of patients (95% CI: 14, 37).ConclusionThis meta-analysis on different second-line ICI-containing therapies in ICI-pretreated mRCC patients supports a modest efficacy and tolerable toxicity. |
| first_indexed | 2024-04-11T07:46:58Z |
| format | Article |
| id | doaj.art-35ee0629c27e4b1aae7fc30852c68701 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T07:46:58Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-35ee0629c27e4b1aae7fc30852c687012022-12-22T04:36:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.996553996553Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysisMaria Papathanassiou0Ioannis Tamposis1Kalliopi K. Exarchou-Kouveli2Panagiota I. Kontou3Anna Tzortzi de Paz4Lampros Mitrakas5Maria Samara6Pantelis G. Bagos7Vassilios Tzortzis8Panagiotis J. Vlachostergios9Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, GreeceDepartment of Computer Science and Biomedical Informatics, University of Thessaly, Lamia, GreeceDepartment of Computer Science and Biomedical Informatics, University of Thessaly, Lamia, GreeceDepartment of Mathematics, University of Thessaly, Lamia, GreeceDepartment of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa, Larissa, GreeceDepartment of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa, Larissa, GreeceDepartment of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, GreeceDepartment of Computer Science and Biomedical Informatics, University of Thessaly, Lamia, GreeceDepartment of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa, Larissa, GreeceDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United StatesIntroductionThe use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA monoclonal antibodies.MethodsElectronic databases, including PubMed, EMBASE, Medline, Web of Science, and Cochrane Library, were comprehensively searched from inception to July 2022. Objective response rates (ORR), progression-free survival (PFS), and ≥ grade 3 adverse events (AEs) were assessed in the meta-analysis, along with corresponding 95% confidence intervals (CIs) and publication bias.ResultsTen studies which contained a total of 500 patients were included. The pooled ORR was 19% (95% CI: 10, 31), and PFS was 5.6 months (95% CI: 4.1, 7.8). There were ≥ grade 3 AEs noted in 25% of patients (95% CI: 14, 37).ConclusionThis meta-analysis on different second-line ICI-containing therapies in ICI-pretreated mRCC patients supports a modest efficacy and tolerable toxicity.https://www.frontiersin.org/articles/10.3389/fonc.2022.996553/fullimmunotherapyimmune checkpoint inhibitorrechallengesalvagesecond-lineVEGF TKI |
| spellingShingle | Maria Papathanassiou Ioannis Tamposis Kalliopi K. Exarchou-Kouveli Panagiota I. Kontou Anna Tzortzi de Paz Lampros Mitrakas Maria Samara Pantelis G. Bagos Vassilios Tzortzis Panagiotis J. Vlachostergios Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis Frontiers in Oncology immunotherapy immune checkpoint inhibitor rechallenge salvage second-line VEGF TKI |
| title | Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis |
| title_full | Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis |
| title_fullStr | Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis |
| title_full_unstemmed | Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis |
| title_short | Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis |
| title_sort | immune based treatment re challenge in renal cell carcinoma a systematic review and meta analysis |
| topic | immunotherapy immune checkpoint inhibitor rechallenge salvage second-line VEGF TKI |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.996553/full |
| work_keys_str_mv | AT mariapapathanassiou immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT ioannistamposis immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT kalliopikexarchoukouveli immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT panagiotaikontou immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT annatzortzidepaz immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT lamprosmitrakas immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT mariasamara immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT pantelisgbagos immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT vassiliostzortzis immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis AT panagiotisjvlachostergios immunebasedtreatmentrechallengeinrenalcellcarcinomaasystematicreviewandmetaanalysis |